https://retacompare.com/news/unregulated-retatrutide-product-linked-to-liver-injury-in-case-report-2 2026-11-03T02:19:59.000Z RetatrutideCompare en 2026-11-03T02:19:59.000Z Unregulated Retatrutide Product Linked to Liver Injury in Case Report Patient Experiences, Retatrutide https://retacompare.com/news/unregulated-retatrutide-product-linked-to-liver-injury-in-case-report 2026-11-03T02:19:59.000Z RetatrutideCompare en 2026-11-03T02:19:59.000Z Unregulated Retatrutide Product Linked to Liver Injury in Case Report Patient Experiences, Retatrutide https://retacompare.com/news/study-indicates-reduced-alcohol-consumption-among-glp-1-users 2026-11-02T21:28:49.000Z RetatrutideCompare en 2026-11-02T21:28:49.000Z Study Indicates Reduced Alcohol Consumption Among GLP-1 Users Patient Experiences, Retatrutide https://retacompare.com/news/ohio-group-advocates-medicaid-coverage-for-glp-1-weight-loss-drugs 2026-11-02T16:47:32.000Z RetatrutideCompare en 2026-11-02T16:47:32.000Z Ohio Group Advocates Medicaid Coverage for GLP-1 Weight-Loss Drugs Market News, Retatrutide https://retacompare.com/news/ohio-group-advocates-for-medicaid-coverage-of-glp-1-weight-loss-drugs 2026-11-02T16:47:32.000Z RetatrutideCompare en 2026-11-02T16:47:32.000Z Ohio Group Advocates for Medicaid Coverage of GLP-1 Weight-Loss Drugs Market News, Retatrutide https://retacompare.com/news/ohio-group-pushes-for-medicaid-coverage-of-glp-1-weight-loss-medications 2026-11-02T16:37:20.000Z RetatrutideCompare en 2026-11-02T16:37:20.000Z Ohio Group Pushes for Medicaid Coverage of GLP-1 Weight-Loss Medications Market News, Retatrutide https://retacompare.com/news/glp-1-drug-coverage-reductions-impact-market-dynamics 2026-11-02T13:54:42.000Z RetatrutideCompare en 2026-11-02T13:54:42.000Z GLP-1 Drug Coverage Reductions Impact Market Dynamics Market News, Retatrutide https://retacompare.com/news/study-assesses-psychological-effects-during-gip-and-glp-1-therapy 2026-11-02T13:30:32.225Z RetatrutideCompare en 2026-11-02T13:30:32.225Z Study Assesses Psychological Effects During GIP and GLP-1 Therapy Patient Experiences, Retatrutide https://retacompare.com/news/updated-meta-analysis-compares-semaglutide-and-placebo-in-obesity-treatment 2026-11-02T13:30:32.225Z RetatrutideCompare en 2026-11-02T13:30:32.225Z Updated Meta-Analysis Compares Semaglutide and Placebo in Obesity Treatment Clinical Trials, Retatrutide https://retacompare.com/news/glp-1-agonists-evolutionary-insights-into-obesity-and-lifestyle-challenges 2026-11-02T13:30:32.225Z RetatrutideCompare en 2026-11-02T13:30:32.225Z GLP-1 Agonists: Evolutionary Insights into Obesity and Lifestyle Challenges Weight Loss, Retatrutide https://retacompare.com/news/glp-1-agonists-show-lower-diabetes-and-heart-risks-compared-to-standard-treatments 2026-11-02T12:00:53.000Z RetatrutideCompare en 2026-11-02T12:00:53.000Z GLP-1 Agonists Show Lower Diabetes and Heart Risks Compared to Standard Treatments Clinical Trials, Retatrutide https://retacompare.com/news/glp-1-drugs-show-potential-in-reducing-type-2-diabetes-risk-for-prediabetics 2026-11-02T10:00:00.000Z RetatrutideCompare en 2026-11-02T10:00:00.000Z GLP-1 Drugs Show Potential in Reducing Type 2 Diabetes Risk for Prediabetics Clinical Trials, Retatrutide https://retacompare.com/news/studies-find-no-fracture-risk-with-glp-1-therapies 2026-11-02T07:13:39.000Z RetatrutideCompare en 2026-11-02T07:13:39.000Z Studies Find No Fracture Risk with GLP-1 Therapies Clinical Trials, Retatrutide https://retacompare.com/news/employers-limit-glp-1-access-andel-and-novo-suggest-alternatives 2026-11-02T07:12:42.000Z RetatrutideCompare en 2026-11-02T07:12:42.000Z Employers Limit GLP-1 Access, Andel and Novo Suggest Alternatives Market News, Retatrutide https://retacompare.com/news/glp-1-stimulates-il-27-in-macrophages-via-pi3k-akt-pathway-activation 2026-11-02T00:00:00.000Z RetatrutideCompare en 2026-11-02T00:00:00.000Z GLP-1 Stimulates IL-27 in Macrophages via PI3K/AKT Pathway Activation Clinical Trials, Retatrutide